A CLINICAL EVALUATION OF THE PRONOVA XR POLYMER FREE SIROLIMUS ELUTING CORONARY STENT SYSTEM IN THE
TREATMENT OF PATIENTS WITH DE NOVO CORONORY ARTERY LESIONS (EURONOVA XR I STUDY)
Jacek Legutko (a)(b), Wojciech Zasada (a)(d), Grzegorz L. Kaluza (e), Grzegorz Heba (a), Lukasz Rzeszutko (a), Jacek Jakala (a),
Jacek Dragan (c), Artur Klecha (b), Dawid Giszterowicz (c), Wojciech Dobrowolski (c), Lukasz Partyka (d), Swaminathan Jayaraman (f),
Dariusz Dudek (a)
(a) Department of Interventional Cardiology, Jagiellonian University, Krakow, Poland
(b) Department of Invasive Cardiology, Electrotherapy and Angiology, Intercard, Nowy Targ, Poland
(c) Department of Invasive Cardiology, Electrotherapy and Angiology, Intercard, Nowy Sa cz, Poland
(d) Krakow Cardiovascular Research Institute, Krakow, Poland
(e) Cardiovascular Research Foundation, New York, NY, USA
(f) Vascular Concepts Limited, UK
RESULT:
50 patients were recruited.
At 6 months, the instent late lumen loss was 0.45 ± 0.41 mm.
Total MACE rate was 6.4% upto 12 months.
CONCLUSION:
Pronova XR polymer free sirolimus eluting stent appeared safe upto
12 months of clinical angiographic & IVUS follow up.
PRODUCTS
PATIENTS